Literature DB >> 35142845

Trans Fatty Acid Biomarkers and Incident Type 2 Diabetes: Pooled Analysis of 12 Prospective Cohort Studies in the Fatty Acids and Outcomes Research Consortium (FORCE).

Heidi T M Lai1,2, Fumiaki Imamura3, Andres V Ardisson Korat4,5, Rachel A Murphy6, Nathan Tintle7,8, Julie K Bassett9, Jiaying Chen10, Janine Kröger11, Kuo-Liong Chien12, Mackenzie Senn13, Alexis C Wood13, Nita G Forouhi3, Matthias B Schulze11,14,15, William S Harris8,16, Ramachandran S Vasan17,18, Frank Hu4,5, Graham G Giles9,19,20, Allison Hodge9, Luc Djousse21, Ingeborg A Brouwer22, Frank Qian23, Qi Sun4,5, Jason H Y Wu24, Matti Marklund1,24,25, Rozenn N Lemaitre26, David S Siscovick27, Amanda M Fretts28, Aladdin H Shadyab29, JoAnn E Manson30,31, Barbara V Howard32, Jennifer G Robinson33, Robert B Wallace33, Nick J Wareham3, Yii-Der Ida Chen34, Jerome I Rotter34, Michael Y Tsai35, Renata Micha1, Dariush Mozaffarian1.   

Abstract

OBJECTIVE: Trans fatty acids (TFAs) have harmful biologic effects that could increase the risk of type 2 diabetes (T2D), but evidence remains uncertain. We aimed to investigate the prospective associations of TFA biomarkers and T2D by conducting an individual participant-level pooled analysis. RESEARCH DESIGN AND METHODS: We included data from an international consortium of 12 prospective cohorts and nested case-control studies from six nations. TFA biomarkers were measured in blood collected between 1990 and 2008 from 25,126 participants aged ≥18 years without prevalent diabetes. Each cohort conducted de novo harmonized analyses using a prespecified protocol, and findings were pooled using inverse-variance weighted meta-analysis. Heterogeneity was explored by prespecified between-study and within-study characteristics.
RESULTS: During a mean follow-up of 13.5 years, 2,843 cases of incident T2D were identified. In multivariable-adjusted pooled analyses, no significant associations with T2D were identified for trans/trans-18:2, relative risk (RR) 1.09 (95% CI 0.94-1.25); cis/trans-18:2, 0.89 (0.73-1.07); and trans/cis-18:2, 0.87 (0.73-1.03). Trans-16:1n-9, total trans-18:1, and total trans-18:2 were inversely associated with T2D (RR 0.81 [95% CI 0.67-0.99], 0.86 [0.75-0.99], and 0.84 [0.74-0.96], respectively). Findings were not significantly different according to prespecified sources of potential heterogeneity (each P ≥ 0.1).
CONCLUSIONS: Circulating individual trans-18:2 TFA biomarkers were not associated with risk of T2D, while trans-16:1n-9, total trans-18:1, and total trans-18:2 were inversely associated. Findings may reflect the influence of mixed TFA sources (industrial vs. natural ruminant), a general decline in TFA exposure due to policy changes during this period, or the relatively limited range of TFA levels.
© 2022 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35142845      PMCID: PMC9114723          DOI: 10.2337/dc21-1756

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   17.152


  33 in total

1.  Intake of a diet high in trans monounsaturated fatty acids or saturated fatty acids. Effects on postprandial insulinemia and glycemia in obese patients with NIDDM.

Authors:  E Christiansen; S Schnider; B Palmvig; E Tauber-Lassen; O Pedersen
Journal:  Diabetes Care       Date:  1997-05       Impact factor: 19.112

2.  The amount and type of dairy product intake and incident type 2 diabetes: results from the EPIC-InterAct Study.

Authors:  Ivonne Sluijs; Nita G Forouhi; Joline W J Beulens; Yvonne T van der Schouw; Claudia Agnoli; Larraitz Arriola; Beverley Balkau; Aurelio Barricarte; Heiner Boeing; H Bas Bueno-de-Mesquita; Françoise Clavel-Chapelon; Francesca L Crowe; Blandine de Lauzon-Guillain; Dagmar Drogan; Paul W Franks; Diana Gavrila; Carlos Gonzalez; Jytte Halkjaer; Rudolf Kaaks; Aurelie Moskal; Peter Nilsson; Kim Overvad; Domenico Palli; Salvatore Panico; José R Quirós; Fulvio Ricceri; Sabina Rinaldi; Olov Rolandsson; Carlotta Sacerdote; María-José Sánchez; Nadia Slimani; Annemieke M W Spijkerman; Birgit Teucher; Anne Tjonneland; María-José Tormo; Rosario Tumino; Daphne L van der A; Stephen J Sharp; Claudia Langenberg; Edith J M Feskens; Elio Riboli; Nicholas J Wareham
Journal:  Am J Clin Nutr       Date:  2012-07-03       Impact factor: 7.045

3.  Food sources of individual plasma phospholipid trans fatty acid isomers: the Cardiovascular Health Study.

Authors:  Renata Micha; Irena B King; Rozenn N Lemaitre; Eric B Rimm; Frank Sacks; Xiaoling Song; David S Siscovick; Dariush Mozaffarian
Journal:  Am J Clin Nutr       Date:  2010-03-10       Impact factor: 7.045

4.  Diet, lifestyle, and genetic risk factors for type 2 diabetes: a review from the Nurses' Health Study, Nurses' Health Study 2, and Health Professionals' Follow-up Study.

Authors:  Andres V Ardisson Korat; Walter C Willett; Frank B Hu
Journal:  Curr Nutr Rep       Date:  2014-12-01

5.  Trans fat intake lowers total cholesterol and high-density lipoprotein cholesterol levels without changing insulin sensitivity index in Wistar rats.

Authors:  Zhiliang Huang; Baowu Wang; Ralphenia D Pace; Seokjoo Yoon
Journal:  Nutr Res       Date:  2009-03       Impact factor: 3.315

6.  Final Determination Regarding Partially Hydrogenated Oils. Notification; declaratory order; extension of compliance date.

Authors: 
Journal:  Fed Regist       Date:  2018-05-21

7.  Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality.

Authors:  Matti Marklund; Jason H Y Wu; Fumiaki Imamura; Liana C Del Gobbo; Amanda Fretts; Janette de Goede; Peilin Shi; Nathan Tintle; Maria Wennberg; Stella Aslibekyan; Tzu-An Chen; Marcia C de Oliveira Otto; Yoichiro Hirakawa; Helle Højmark Eriksen; Janine Kröger; Federica Laguzzi; Maria Lankinen; Rachel A Murphy; Kiesha Prem; Cécilia Samieri; Jyrki Virtanen; Alexis C Wood; Kerry Wong; Wei-Sin Yang; Xia Zhou; Ana Baylin; Jolanda M A Boer; Ingeborg A Brouwer; Hannia Campos; Paulo H M Chaves; Kuo-Liong Chien; Ulf de Faire; Luc Djoussé; Gudny Eiriksdottir; Naglaa El-Abbadi; Nita G Forouhi; J Michael Gaziano; Johanna M Geleijnse; Bruna Gigante; Graham Giles; Eliseo Guallar; Vilmundur Gudnason; Tamara Harris; William S Harris; Catherine Helmer; Mai-Lis Hellenius; Allison Hodge; Frank B Hu; Paul F Jacques; Jan-Håkan Jansson; Anya Kalsbeek; Kay-Tee Khaw; Woon-Puay Koh; Markku Laakso; Karin Leander; Hung-Ju Lin; Lars Lind; Robert Luben; Juhua Luo; Barbara McKnight; Jaakko Mursu; Toshiharu Ninomiya; Kim Overvad; Bruce M Psaty; Eric Rimm; Matthias B Schulze; David Siscovick; Michael Skjelbo Nielsen; Albert V Smith; Brian T Steffen; Lyn Steffen; Qi Sun; Johan Sundström; Michael Y Tsai; Hugh Tunstall-Pedoe; Matti I J Uusitupa; Rob M van Dam; Jenna Veenstra; W M Monique Verschuren; Nick Wareham; Walter Willett; Mark Woodward; Jian-Min Yuan; Renata Micha; Rozenn N Lemaitre; Dariush Mozaffarian; Ulf Risérus
Journal:  Circulation       Date:  2019-05-21       Impact factor: 29.690

8.  Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies.

Authors:  Jason H Y Wu; Matti Marklund; Fumiaki Imamura; Nathan Tintle; Andres V Ardisson Korat; Janette de Goede; Xia Zhou; Wei-Sin Yang; Marcia C de Oliveira Otto; Janine Kröger; Waqas Qureshi; Jyrki K Virtanen; Julie K Bassett; Alexis C Frazier-Wood; Maria Lankinen; Rachel A Murphy; Kalina Rajaobelina; Liana C Del Gobbo; Nita G Forouhi; Robert Luben; Kay-Tee Khaw; Nick Wareham; Anya Kalsbeek; Jenna Veenstra; Juhua Luo; Frank B Hu; Hung-Ju Lin; David S Siscovick; Heiner Boeing; Tzu-An Chen; Brian Steffen; Lyn M Steffen; Allison Hodge; Gudny Eriksdottir; Albert V Smith; Vilmunder Gudnason; Tamara B Harris; Ingeborg A Brouwer; Claudine Berr; Catherine Helmer; Cecilia Samieri; Markku Laakso; Michael Y Tsai; Graham G Giles; Tarja Nurmi; Lynne Wagenknecht; Matthias B Schulze; Rozenn N Lemaitre; Kuo-Liong Chien; Sabita S Soedamah-Muthu; Johanna M Geleijnse; Qi Sun; William S Harris; Lars Lind; Johan Ärnlöv; Ulf Riserus; Renata Micha; Dariush Mozaffarian
Journal:  Lancet Diabetes Endocrinol       Date:  2017-10-12       Impact factor: 32.069

9.  Circulating and dietary trans fatty acids and incident type 2 diabetes in older adults: the Cardiovascular Health Study.

Authors:  Qianyi Wang; Fumiaki Imamura; Wenjie Ma; Molin Wang; Rozenn N Lemaitre; Irena B King; Xiaoling Song; Mary L Biggs; Joseph A Delaney; Kenneth J Mukamal; Luc Djousse; David S Siscovick; Dariush Mozaffarian
Journal:  Diabetes Care       Date:  2015-03-17       Impact factor: 19.112

10.  n-3 Fatty Acid Biomarkers and Incident Type 2 Diabetes: An Individual Participant-Level Pooling Project of 20 Prospective Cohort Studies.

Authors:  Frank Qian; Andres V Ardisson Korat; Fumiaki Imamura; Matti Marklund; Nathan Tintle; Jyrki K Virtanen; Xia Zhou; Julie K Bassett; Heidi Lai; Yoichiro Hirakawa; Kuo-Liong Chien; Alexis C Wood; Maria Lankinen; Rachel A Murphy; Cecilia Samieri; Kamalita Pertiwi; Vanessa D de Mello; Weihua Guan; Nita G Forouhi; Nick Wareham; InterAct Consortium Frank B Hu; Ulf Riserus; Lars Lind; William S Harris; Aladdin H Shadyab; Jennifer G Robinson; Lyn M Steffen; Allison Hodge; Graham G Giles; Toshiharu Ninomiya; Matti Uusitupa; Jaakko Tuomilehto; Jaana Lindström; Markku Laakso; David S Siscovick; Catherine Helmer; Johanna M Geleijnse; Jason H Y Wu; Amanda Fretts; Rozenn N Lemaitre; Renata Micha; Dariush Mozaffarian; Qi Sun
Journal:  Diabetes Care       Date:  2021-03-03       Impact factor: 19.112

View more
  2 in total

1.  Plasma Industrial and Ruminant Trans Fatty Acids and Incident Type 2 Diabetes in the EPIC-Potsdam Cohort.

Authors:  Marcela Prada; Clemens Wittenbecher; Fabian Eichelmann; Andreas Wernitz; Olga Kuxhaus; Janine Kröger; Cornelia Weikert; Matthias B Schulze
Journal:  Diabetes Care       Date:  2022-04-01       Impact factor: 17.152

Review 2.  [Saturated fatty acids and cardiovascular risk : Is a revision of the recommendations on nutrition indicated?]

Authors:  N Worm; O Weingärtner; C Schulze; K Lechner
Journal:  Herz       Date:  2021-09-23       Impact factor: 1.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.